Skip to main content

177Lu-PSMA-617

177Lu-PSMA-617 in People With Gliomas

  • RegistryNCT07223034
  • PhasePhase 1
  • StatusRecruiting
  • ConditionGlioma
  • SponsorMemorial Sloan Kettering Cancer Center
How 177Lu-PSMA-617 worksNCT072230341 min

What the film says

Read the transcript

This study is for adults with a type of glioma called IDH wild type, who have finished surgery and radiation.

The idea: carry radiation straight to the tumor cells. A radioactive medicine, lutetium-177 PSMA-617, is built to seek a protein called PSMA. The tumor sample is tested first, and only tumors that stain positive for PSMA qualify.

Patients receive two to six doses, four weeks apart, along with standard temozolomide chemotherapy, then PSMA PET and MRI scans. The study reports side effects. At Memorial Sloan Kettering in New York, Brandon Imber leads it.

Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT07223034

    Adults with IDH wild type glioma who finished surgery and radiation; Radioactive medicine lutetium-177 PSMA-617 seeks PSMA; Tumor sample tested first; PSMA-positive only; Two to six doses, four weeks apart, with temozolomide (+3 more lines)

  • PaperTargeted Radionuclide Therapy in Glioblastoma

    Zhao X. ACS Appl Mater Interfaces, 2024

    Radioactive medicine lutetium-177 PSMA-617 seeks PSMA

The drug

What is being tested.

This agent will be given for 2-6 total doses, spaced 4 weeks (+/-1 week) apart. This will be administered on the 2nd day of the first two cycles of SOC adjuvant temozolomide.

Patients will begin taking Temozolomide orally on the first 5 days of each 28-day cycle. The first dose will be given the evening before the first infusion of 177Lu-PSMA- 617.

The study

How the trial runs.

The researchers are doing this study to find out whether the radiopharmaceutical therapy (RPT) 177Lu-PSMA-617 is a safe treatment for people with IDH wild type glioma.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Confirmed histologic diagnosis of a WHO grade 2-4 glioma that is IDH1 R132H-wildtype, including the following:
  • Diffuse astrocytoma, IDH-wildtype (grade 2-4)
  • Glioblastoma, IDH-wildtype
  • Diffuse midline glioma, H3 K27-altered
  • Diffuse hemispheric glioma, H3 G34-mutant
  • Diffuse pediatric-type high-grade glioma, H3-wildtype and IDH-wildtype PSMA positive pathological stain (by immunohistochemistry) of baseline (pre-radiotherapy) resection or biopsy sample

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.